Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene

Sunwen Chou, Laura C. Van Wechel, Heather M. Lichy, Gail I. Marousek

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

A new recombinant phenotyping method was developed for the analysis of drug resistance mutations in human cytomegalovirus (CMV). CMV strain T2211 was derived from strain AD169 by inserting unique restriction sites and a secreted alkaline phosphatase (SEAP) reporter gene for rapid viral quantitation. Specific viral UL97 and pol gene mutations were transferred by recombination into T2211, and their drug resistance phenotypes (for ganciclovir, foscarnet, or cidofovir) were determined by the drug concentrations required to reduce supernatant SEAP activity by 50% (IC50). Changes in the IC50 conferred by the mutations tested (UL97 M460V, C592G, A594V, and L595S and pol del981-2) were similar to those previously reported in marker transfer and conventional plaque reduction assays. The combination of UL97 C592G and pol del981-2 conferred much higher ganciclovir resistance than either mutation alone. The UL97 polymorphism D605E had no measurable effect on ganciclovir susceptibility, alone or in combination with common UL97 resistance mutations. Transfer into strain T2211 facilitates the phenotyping of newly observed mutations, combinations of mutations, and clinical CMV sequences without an accompanying viral isolate.

Original languageEnglish (US)
Pages (from-to)2710-2715
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume49
Issue number7
DOIs
StatePublished - Jul 2005

Fingerprint

Cytomegalovirus
Reporter Genes
Drug Resistance
Viruses
Mutation
Ganciclovir
Inhibitory Concentration 50
Alkaline Phosphatase
pol Genes
Foscarnet
Viral Genes
Genetic Recombination
Phenotype
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. / Chou, Sunwen; Van Wechel, Laura C.; Lichy, Heather M.; Marousek, Gail I.

In: Antimicrobial Agents and Chemotherapy, Vol. 49, No. 7, 07.2005, p. 2710-2715.

Research output: Contribution to journalArticle

Chou, Sunwen ; Van Wechel, Laura C. ; Lichy, Heather M. ; Marousek, Gail I. / Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. In: Antimicrobial Agents and Chemotherapy. 2005 ; Vol. 49, No. 7. pp. 2710-2715.
@article{b6ebb6eb0564434fb51ef3f14676a338,
title = "Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene",
abstract = "A new recombinant phenotyping method was developed for the analysis of drug resistance mutations in human cytomegalovirus (CMV). CMV strain T2211 was derived from strain AD169 by inserting unique restriction sites and a secreted alkaline phosphatase (SEAP) reporter gene for rapid viral quantitation. Specific viral UL97 and pol gene mutations were transferred by recombination into T2211, and their drug resistance phenotypes (for ganciclovir, foscarnet, or cidofovir) were determined by the drug concentrations required to reduce supernatant SEAP activity by 50{\%} (IC50). Changes in the IC50 conferred by the mutations tested (UL97 M460V, C592G, A594V, and L595S and pol del981-2) were similar to those previously reported in marker transfer and conventional plaque reduction assays. The combination of UL97 C592G and pol del981-2 conferred much higher ganciclovir resistance than either mutation alone. The UL97 polymorphism D605E had no measurable effect on ganciclovir susceptibility, alone or in combination with common UL97 resistance mutations. Transfer into strain T2211 facilitates the phenotyping of newly observed mutations, combinations of mutations, and clinical CMV sequences without an accompanying viral isolate.",
author = "Sunwen Chou and {Van Wechel}, {Laura C.} and Lichy, {Heather M.} and Marousek, {Gail I.}",
year = "2005",
month = "7",
doi = "10.1128/AAC.49.7.2710-2715.2005",
language = "English (US)",
volume = "49",
pages = "2710--2715",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "7",

}

TY - JOUR

T1 - Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene

AU - Chou, Sunwen

AU - Van Wechel, Laura C.

AU - Lichy, Heather M.

AU - Marousek, Gail I.

PY - 2005/7

Y1 - 2005/7

N2 - A new recombinant phenotyping method was developed for the analysis of drug resistance mutations in human cytomegalovirus (CMV). CMV strain T2211 was derived from strain AD169 by inserting unique restriction sites and a secreted alkaline phosphatase (SEAP) reporter gene for rapid viral quantitation. Specific viral UL97 and pol gene mutations were transferred by recombination into T2211, and their drug resistance phenotypes (for ganciclovir, foscarnet, or cidofovir) were determined by the drug concentrations required to reduce supernatant SEAP activity by 50% (IC50). Changes in the IC50 conferred by the mutations tested (UL97 M460V, C592G, A594V, and L595S and pol del981-2) were similar to those previously reported in marker transfer and conventional plaque reduction assays. The combination of UL97 C592G and pol del981-2 conferred much higher ganciclovir resistance than either mutation alone. The UL97 polymorphism D605E had no measurable effect on ganciclovir susceptibility, alone or in combination with common UL97 resistance mutations. Transfer into strain T2211 facilitates the phenotyping of newly observed mutations, combinations of mutations, and clinical CMV sequences without an accompanying viral isolate.

AB - A new recombinant phenotyping method was developed for the analysis of drug resistance mutations in human cytomegalovirus (CMV). CMV strain T2211 was derived from strain AD169 by inserting unique restriction sites and a secreted alkaline phosphatase (SEAP) reporter gene for rapid viral quantitation. Specific viral UL97 and pol gene mutations were transferred by recombination into T2211, and their drug resistance phenotypes (for ganciclovir, foscarnet, or cidofovir) were determined by the drug concentrations required to reduce supernatant SEAP activity by 50% (IC50). Changes in the IC50 conferred by the mutations tested (UL97 M460V, C592G, A594V, and L595S and pol del981-2) were similar to those previously reported in marker transfer and conventional plaque reduction assays. The combination of UL97 C592G and pol del981-2 conferred much higher ganciclovir resistance than either mutation alone. The UL97 polymorphism D605E had no measurable effect on ganciclovir susceptibility, alone or in combination with common UL97 resistance mutations. Transfer into strain T2211 facilitates the phenotyping of newly observed mutations, combinations of mutations, and clinical CMV sequences without an accompanying viral isolate.

UR - http://www.scopus.com/inward/record.url?scp=21444434735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21444434735&partnerID=8YFLogxK

U2 - 10.1128/AAC.49.7.2710-2715.2005

DO - 10.1128/AAC.49.7.2710-2715.2005

M3 - Article

VL - 49

SP - 2710

EP - 2715

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 7

ER -